PRTODAY / NewswireToday Free press release distribution service network

More news: Research
Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Lauds Advanced Cell Diagnostics for its Highly Innovative in Situ Biomarker Detection Assay Kit - RNAscope provides the first opportunity to profile single cell gene expression in situ, unlocking the full potential of RNA biomarkers for personalized medicine - ACDbio.com / Awards.Frost.com
Frost & Sullivan Lauds Advanced Cell Diagnostics for its Highly Innovative in Situ Biomarker Detection Assay Kit

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2011/11/10 - RNAscope provides the first opportunity to profile single cell gene expression in situ, unlocking the full potential of RNA biomarkers for personalized medicine - ACDbio.com / Awards.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the in situ biomarker detection assay market, Frost & Sullivan recognizes Advanced Cell Diagnostics, Inc. with the 2011 North American Frost & Sullivan Technology Innovation Award for its RNAscope platform.

Advanced Cell Diagnostics' RNAscope formalin-fixed and paraffin-embedded (FFPE) Assay Kit, a novel multiplex nucleic acid in situ hybridization technology, is based on a proprietary and unique probe design and signal amplification methodology. It is designed to detect RNA biomarkers in routine FFPE tissue specimens with single molecule sensitivity and at single cell resolution.

"RNAscope provides the first opportunity to profile single cell gene expression in situ, leveraging the full potential of RNA biomarker technology," said Frost & Sullivan Senior Research Analyst Cecilia Van Cauwenberghe. "This technology offers unique opportunities by targeting the molecular signature of every cell within the intricate cellular structure and tissue architecture evidenced in clinical specimens."

Furthermore, the RNAscope technology platform excels over conventional assays by reaching significantly high levels of specificity and sensitivity in detecting virtually any gene in the human transcriptome in situ, while simultaneously enabling quantification of multiple mRNA transcripts at a single cell level. This constitutes a paradigm shift in molecular pathology and represents a breakthrough in personalized medicine.

RNAscope offers end-users an enhanced toolset for research and development applications and their further translation to clinical diagnostics. Among its advantages are rapid assay development; ultimate sensitivity, including single molecule detection in situ; high specificity, allowing the distinguishing of highly homologous genes; and multiplexing capability through the simultaneous detection of multiple targets.
"Other strengths include quantitative analysis, enabling the detection of each target to be quantified on a per cell basis," said Cecilia Van Cauwenberghe. "In addition, it offers colorimetric or fluorescent readout under bright field or fluorescent microscope, broad sample type spectrum, as well as speed and throughput compatibility with fully automated walk away assay systems."

RNAscope offers end-users high levels of flexibility and customization capabilities that adapt and evolve with the drug discovery and development process, significantly contributing to the acceleration of biomarker validation.

"The technology has been demonstrated to achieve RT-PCR-level sensitivity and specificity," said Cecilia Van Cauwenberghe. "RNAscope is viewed as being over 100-fold more sensitive than traditional non-isotopic ISH methods."

In the near future, RNAscope can be deployed by pathologists as part of their laboratory routine for molecular diagnostics. According to a recent clinical study utilizing RNAscope technology to detect human papillomavirus (HPV) E6/E7 mRNA in routine clinical specimens of head and neck cancer, the HPV status determined by the RNAscope HPV test was highly predictive of patient outcome. It revealed high concordance to a surrogate protein marker and much higher sensitivity than an existing DNA-based test.

In recognition of these features, Frost & Sullivan is proud to present Advanced Cell Diagnostics, Inc. with the 2011 Technology Innovation Award in the North American in situ biomarker detection assay market. Each year, Frost & Sullivan presents this award to the company that demonstrates uniqueness in developing a technology, which significantly impacts both the functionality and the customer value of new products and applications. The award lauds the relevance of the innovation to the industry.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Advanced Cell Diagnostics, Inc. (ACD)
Headquartered in Hayward, California, Advanced Cell Diagnostics, Inc. (acdbio.com) has positioned as a leader in the emerging field of molecular pathology, through its innovative developments in cell- and tissue-based diagnostic tests for personalized medicine. The Company's proprietary technology, RNAscope®, represents the first multiplex fluorescent and chromogenic in situ hybridization platform focus on the detection and quantification of RNA biomarkers in situ at single molecule level. ACD is committed in the validation of biomarkers for targeted therapeutic developments in cancer and other diseases. Responsible collaboration lines with pharmaceutical and biotechnology companies provides the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics, in addition to ACD's internal programs to develop proprietary diagnostic tests.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Lauds Advanced Cell Diagnostics for its Highly Innovative in Situ Biomarker Detection Assay Kit

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan | Advanced Cell Diagnostics
Publisher Contact: Mireya Espinoza 
210-247-3870 mireya.espinoza[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Research Most Recent Related Newswires:

DSM-Niaga Ready for Commercial Scale Production of 100%-recyclable Carpets
DSM Dyneema Introduces Whole New Level of Cut Protection with Black Dyneema® Diamond Technology
DSM Presents Sustainable and Healthy Dairy Solutions At FoodTech 2016
Frost & Sullivan Highlights GENEWIZ's Commitment to Providing Cutting-edge Services in the Life Science Research Services Market
DSM to Present its Latest Advances in Skin Biochemistry At IFSCC Conference
DSM Launches ForTii® Ace Next Generation High Performance Polyamides
DSM Launches New Cultures to Reduce Cheese Ripening Time
DSM Launches New 3C Technology to Reinvigorate Omega-3 Supplements Category
DSM to Highlight its Health and Indulgence Solutions for Baked Goods At IBIE
DSM Welcomes EU Novel Foods Approval for Heart Health Antioxidant
DSM Dyneema Successfully Defends Key Patent Against Competitor Challenge
DSM Expands its Automotive Electronics Portfolio with High-flow Akulon PA66
BD Expands Portfolio of Reproductive and Sexually Transmitted Infections Solutions
BD Announces New Software Release for Pyxis Enterprise Solution
DSM Opens its Asia Pacific Personal Care Technical & Application Center in Shanghai

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  NAKIVO, Inc.





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)